Supplementary data: Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review

<b>These are peer-reviewed supplementary materials for the article '</b><b>Six-minute walk test as clinical end point in </b><b>cardiomyopathy clinical trials, including </b><b>ATTR-CM: a systematic literature review' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Table S1:</b> Embase search strategy: combining 6MWT, mortality, hospitalization, and HF.<b>Table S2: </b>Medline search strategy: combining 6MWT, mortality, hospitalization, and HF.<b>Table S3: </b>Gray literature – Conferences searched.<b>Table S4: </b>JBI Risk of bias assessment — randomized controlled trials<b>Table S5: </b>JBI Risk of bias assessment — cross sectional<b>Table S6: </b>JBI Risk of bias assessment — cohort<b>Table S7: </b>Study and population characteristics<b>Table S8: </b>6MWT and hospitalization: separate outcomes<b>Table S9: </b>6MWT and mortality: separate outcomes<b>Aim:</b> The six-minute walk test (6MWT) is a common measure of functional capacity in patients with heart failure (HF). Primary clinical study end points in cardiomyopathy (CM) trials, including transthyretin-mediated amyloidosis with CM (ATTR-CM), are often limited to hospitalization and mortality. <b>Objective: </b>To investigate the relationship between the 6MWT and hospitalization or mortality in CM, including ATTR-CM. <b>Method: </b>A PRISMA-guided systematic literature review was conducted using search terms for CM, 6MWT, hospitalization and mortality. <b>Results: </b>Forty-one studies were identified that reported 6MWT data and hospitalization or mortality data for patients with CM. The data suggest that a greater 6MWT distance is associated with a reduced risk of hospitalization or mortality in CM. Conclusion: The 6MWT is an accepted alternative end point in CM trials, including ATTR-CM.